Phosphodiesterase-4 Inhibitors in the Treatment of Inflammatory Lung Disease

Drugs

Volumn 63, Issue 23, 2003, Pages 2575-2594

  Spina, Domenico ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; 4 (3 CHLOROPHENYL) 1,7 DIETHYLPYRIDO[2,3 D]PYRIMIDIN 2(1H) ONE; 4 [2 [3 (CYCLOPENTYLOXY) 4 METHOXYPHENYL] 2 PHENYLETHYL]PYRIDINE; 8 [[1 (3,4 DIMETHOXYPHENYL) 2 HYDROXYETHYL]AMINO] 3,7 DIHYDRO 7 (2 METHOXYETHYL) 1,3 DIMETHYL 1H PURINE 2,6 DIONE; ATIZORAM; BENAFENTRINE; CILOMILAST; CILOSTAZOL; CYCLIC AMP; CYCLIC NUCLEOTIDE; IBUDILAST; LOPRINONE; PHOSPHODIESTERASE; PHOSPHODIESTERASE IV INHIBITOR; PHOSPHODIESTERASE V; PICLAMILAST; ROFLUMILAST; ROLIPRAM; SILDENAFIL; THEOPHYLLINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ZARDAVERINE;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; ATOPIC DERMATITIS; BINDING AFFINITY; BINDING SITE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; ERECTILE DYSFUNCTION; FORCED EXPIRATORY VOLUME; HUMAN; INFLAMMATION; LUNG DISEASE; NAUSEA; PATHOGENESIS; PNEUMONIA; PROTEIN EXPRESSION; RESPIRATORY TRACT DISEASE; REVIEW; SECOND MESSENGER; VOMITING;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; ASTHMA; CLINICAL TRIALS; CYCLIC AMP; HUMANS; LUNG DISEASES; PHOSPHODIESTERASE INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EMESIS;

EID: 0344513958     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200363230-00002     Document Type: Review

References (176)

1. Stief CG. Phosphodiesterase inhibitors in the treatment of erectile dysfunction. Drugs Today (Barc) 2000; 36: 93-9
2. Souness JE, Aldous D, Sargent C. Immunosuppressive and antiinflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. Immunopharmacology 2000; 47: 127-62
3. Dyke HJ, Montana JG. Update on the therapeutic potential of PDE4 inhibitors. Expert Opin Investig Drugs 2002; 11: 1-13
4. Norman P. PDE4 inhibitors 2001: patent and literature activity 2000-Sep 2001. Expert Opin Ther Patents 2002; 12: 93-111
5. Torphy TJ, Barnette MS, Underwood DC, et al. Ariflow™ (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic. Pulm Pharmacol Ther 1999; 12: 131-5
6. Compton CH, Gubb J, Nieman R, et al. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study. Lancet 2001; 358: 265-70
7. Schmidt BM, Kusma M, Feuring M, et al. The phosphodiesterase 4 inhibitor roflumilast is effective in the treatment of allergic rhinitis. J Allergy Clin Immunol 2001; 108: 530-6
8. Timmer W, Leclerc V, Birraux G, et al. The new phosphodies-terase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-alpha ex vivo. J Clin Pharmacol 2002; 42: 297-303
9. Aoki M, Fukunaga M, Sugimoto T, et al. Studies on mechanisms of low emetogenicity of YM976, a novel phosphodiesterase type 4 inhibitor. J Pharmacol Exp Ther 2001; 298: 1142-9
10. Essayan DM. Cyclic nucleotide phosphodiesterases. J Allergy Clin Immunol 2001; 108: 671-80
11. Hatzelmann A, Schudt C. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 2001; 297: 267-79
12. Trifilieff A, Wyss D, Walker C, et al. Pharmacological profile of a novel phosphodiesterase 4 inhibitor, 4-(8-benzo[1,2,5]oxadiazol-5-yl-[1,7] naphthyridin-6-yl)-benzoic acid (NVP-ABE171), a 1,7-nNaphthyridine derivative, with anti-inflammatory activities. J Pharmacol Exp Ther 2002; 301: 241-8
13. Ohta K, Yamashita N. Apoptosis of eosinophils and lymphocytes in allergic inflammation. J Allergy Clin Immunol 1999; 104: 14-21
14. Takeuchi M, Tatsumi Y, Kitaichi K, et al. Selective phosphodiesterase type 4 inhibitors reduce the prolonged survival of eosinophils stimulated by granulocyte-macrophage colony-stimulating factor. Biol Pharm Bull 2002; 25: 184-7
15. Essayan DM, Huang SK, Undem BJ, et al. Modulation of antigen-and mitogen-induced proliferative responses of peripheral blood mononuclear cells by nonselective and isozyme selective cyclic nucleotide phosphodiesterase inhibitors. J Immunol 1994; 153: 3408-16
16. Essayan DM, Kagey-Sobotka A, Lichtenstein LM, et al. Differential regulation of human antigen-specific Th1 and Th2 lymphocyte responses by isozyme selective cyclic nucleotide phosphodiesterase inhibitors. J Pharmacol Exp Ther 1997; 282: 505-12
17. Crocker IC, Townley RG, Khan MM. Phosphodiesterase inhibitors suppress proliferation of peripheral blood mononuclear cells and interleukin-4 and -5 secretion by human T-helper type 2 cells. Immunopharmacology 1996; 31: 223-35
18. Bielekova B, Lincoln A, McFarland H, et al. Therapeutic potential of phosphodiesterase-4 and -3 inhibitors in Th1-mediated autoimmune diseases. J Immunol 2000; 164: 1117-24
19. Tenor H, Hatzelmann A, Church MK, et al. Effects of theophylline and rolipram on leukotriene C4 (LTC4) synthesis and chemotaxis of human eosinophils from normal and atopic subjects. Br J Pharmacol 1996; 118: 1727-35
20. Schmidt DT, Watson N, Dent G, et al. The effect of selective and non-selective phosphodiesterase inhibitors on allergenand leukotriene C(4)-induced contractions in passively sensitized human airways. Br J Pharmacol 2000; 131: 1607-18
21. Qian Y, Girard V, Martin CA, et al. Rolipram, but not siguazodan or zaprinast, inhibits the excitatory noncholinergic neurotransmission in guinea-pig bronchi. Eur Respir J 1994; 7: 306-10
22. Undem BJ, Meeker SN, Chen J. Inhibition of neurally mediated nonadrenergic, noncholinergic contractions of guinea pig bronchus by isozyme-selective phosphodiesterase inhibitors. J Pharmacol Exp Ther 1994; 271: 811-7
23. Spina D, Harrison S, Page CP. Regulation by phosphodiesterase isoenzymes of non-adrenergic non-cholinergic contraction in guinea-pig isolated main bronchus. Br J Pharmacol 1995; 116: 2334-40
24. Fuhrmann M, Jahn H-U, Seybold J, et al. Identification and function of cyclic nucleotide phosphodiesterase isoenzymes in airway epithelial cells. Am J Respir Cell Mol Biol 1999; 20: 292-302
25. Gantner F, Schudt C, Wendel A, et al. Characterization of the phosphodiesterase (PDE) pattern of in vitro-generated human dendritic cells (DC) and the influence of PDE inhibitors on DC function. Pulm Pharmacol Ther 1999; 12: 377-86
26. Blease K, Burke-Gaffney A, Hellewell PG. Modulation of cell adhesion molecule expression and function on human lung microvascular endothelial cells by inhibition of phosphodiesterases 3 and 4. Br J Pharmacol 1998; 124: 229-37
27. Fujii K, Kohrogi H, Iwagoe H, et al. Novel phosphodiesterase 4 inhibitor T-440 reverses and prevents human bronchial contraction induced by allergen. J Pharmacol Exp Ther 1998: 284: 162-9
28. Suttorp N, Ehreiser P, Hippenstiel S, et al. Hyperpermeability of pulmonary endothelial monolayer: protective role of phosphodiesterase isoenzymes 3 and 4. Lung 1996; 174: 181-94
29. Lidington E, Nohammer C, Dominguez M, et al. Inhibition of the transendothelial migration of human lymphocytes but not monocytes by phosphodiesterase inhibitors. Clin Exp Immunol 1996; 104: 66-71
30. Boichot E, Wallace JL, Germain N, et al. Anti-inflammatory activities of a new series of selective phosphodiesterase 4 inhibitors derived from 9-benzyladenine. J Pharmacol Exp Ther 2000; 292: 647-53
31. Pang L, Knox AJ. Regulation of TNF-alpha-induced eotaxin release from cultured human airway smooth muscle cells by beta2-agonists and corticosteroids. FASEB J 2001; 15: 261-9
32. Griswold DE, Webb EF, Breton J, et al. Effect of selective phosphodiesterase type IV inhibitor, rolipram, on fluid and cellular phases of inflammatory response. Inflammation 1993; 17: 333-44
33. Platzer C, Meisel C, Vogt K, et al. Up-regulation of monocytic IL-10 by tumor necrosis factor-alpha and cAMP elevating drugs. Int Immunol 1995; 7: 517-23
34. Haddad JJ, Land SC, Tarnow-Mordi WO, et al. Immunopharmacological potential of selective phosphodiesterase inhibition: I. Differential regulation of lipopolysaccharide-mediated proinflammatory cytokine (interleukin-6 and tumor necrosis factor-alpha) biosynthesis in alveolar epithelial cells. J Pharmacol Exp Ther 2002; 300: 559-66
35. Schade FU, Schudt C. The specific type III and IV phosphodiesterase inhibitor zardaverine suppresses formation of tumor necrosis factor by macrophages. Eur J Pharmacol 1993; 230: 9-14
36. Diaz-Granados N, Howe K, Lu J, et al. Dextran sulfate sodium-induced colonic histopathology, but not altered epithelial ion transport, is reduced by inhibition of phosphodiesterase activity. Am J Pathol 2000; 156: 2169-77
37. Kelley TJ, al Nakkash L, Drumm ML. CFTR-mediated chloride permeability is regulated by type III phosphodiesterases in airway epithelial cells. Am J Respir Cell Mol Biol 1995; 13: 657-64
38. Derian CK, Santulli RJ, Rao PE, et al. Inhibition of chemotactic peptide-induced neutrophil adhesion to vascular endothelium by cAMP modulators. J Immunol 1995; 154: 308-17
39. Armstrong RA. Investigation of the inhibitory effects of PGE2 and selective EP agonists on chemotaxis of human neutrophils. Br J Pharmacol 1995; 116: 2903-8
40. Au BT, Teixeira MM, Collins PD, et al. Effect of PDE4 inhibitors on zymosan-induced IL-8 release from human neutrophils: synergism with prostanoids and salbutamol. Br J Pharmacol 1998; 123: 1260-6
41. Spina D, Landells LJ, Page CP. The role of phosphodiesterase isoenzymes in health and in atopic disease. In: August T, editor. Advances in pharmacology. San Diego (CA): Academic Press Inc., 1998: 33-89
42. Rabe KF, Tenor H, Dent G, et al. Phosphodiesterase isozymes modulating inherent tone in human airways: identification and characterization. Am J Physiol 1993; 264: L458-64
43. Weston MC, Anderson N, Peachell PT. Effects of phosphodiesterase inhibitors on human lung mast cell and basophil function. Br J Pharmacol 1997; 121: 287-95
44. Gantner F, Tenor H, Gekeler V, et al. Phosphodiesterase profiles of highly purified human peripheral blood leukocyte populations from normal and atopic individuals: a comparative study. J Allergy Clin Immunol 1997; 100: 527-35
45. Gantner F, Gotz C, Gekeler V, et al. Phosphodiesterase profile of human B lymphocytes from normal and atopic donors and the effects of PDE inhibition on B cell proliferation. Br J Pharmacol 1998; 123: 1031-8
46. Souness JE, Griffin M, Maslen C, et al. Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNFα generation from human monocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer. Br J Pharmacol 1996; 118: 649-58
47. Manning CD, McLaughlin MM, Livi GP, et al. Prolonged beta adrenoceptor stimulation up-regulates cAMP phosphodiesterase activity in human monocytes by increasing mRNA and protein for phosphodiesterases 4A and 4B. J Pharmacol Exp Ther 1996; 276: 810-8
48. Wang P, Wu P, Ohleth KM, et al. Phosphodiesterase 4B2 is the predominant phosphodiesterase species and undergoes differential regulation of gene expression in human monocytes and neutrophils. Mol Pharmacol 1999; 56: 170-4
49. Engels P, Fichtel K, Lubbert H. Expression and regulation of human and rat phosphodiesterase type IV isogenes. FEBS Lett 1994; 350: 291-5
50. Gantner F, Kupferschmidt R, Schudt C, et al. In vitro differentiation of human monocytes to macrophages: change of PDE profile and its relationship to suppression of tumour necrosis factor-alpha release by PDE inhibitors. Br J Pharmacol 1997; 121: 221-31
51. Obernolte R, Ratzliff J, Baecker PA, et al. Multiple splice variants of phosphodiesterase PDE4C cloned from human lung and testis. Biochemica Biophysica Acta 1997; 1353: 287-97
52. Takahashi M, Terwilliger R, Lane C, et al. Chronic antidepressant administration increases the expression of cAMP-specific phosphodiesterase 4A and 4B isoforms. J Neurosci 1999; 19: 610-8
53. Cherry JA, Davis RL. Cyclic AMP phosphodiesterases are localized in regions of the mouse brain associated with reinforcement, movement and affect. J Comp Neurol 1999; 407: 287-301
54. Lamontagne S, Meadows E, Luk P, et al. Localization of phosphodiesterase-4 isoforms in the medulla and nodose ganglion of the squirrel monkey. Brain Res 2001; 920: 84-96
55. Wright LC, Seybold J, Robichaud A, et al. Phosphodiesterase expression in human epithelial cells. Am J Physiol 1998; 275: L694-700
56. Torphy TJ. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 1998; 157: 351-70
57. Houslay MD. PDE4 cAMP-specific phosphodiesterases. Prog Nucleic Acid Res Mol Biol 2001; 69: 249-315
58. Jacobitz S, McLaughlin MM, Livi GP, et al. Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding. Mol Pharmacol 1996; 50: 891-9
59. Lenhard JM, Kassel DB, Rocque WJ, et al. Phosphorylation of a cAMP-specific phosphodiesterase (HSPDE4B2B) by mitogen-activatedprotein kinase. Biochem J 1996; 319: 751-8
60. Rocque WJ, Tian G, Wiseman JS, et al. Human recombinant phosphodiesterase 4B2B binds (R)-rolipram at a single site with two affinities. Biochemistry 1997; 36: 14250-61
61. Owens RJ, Caterall C, Batty D, et al. Human phosphodiesterase 4A: characterization of full-length and truncated enzymes expressed in COS cells. Biochem J 1997; 326: 53-60
62. Xu RX, Hassell AM, Vanderwall D, et al. Atomic structure of PDE4: insights into phosphodiesterase mechanism a specificity. Science 2000; 288: 1822-5
63. Laliberte F, Han Y, Govindaragan A, et al. Conformational difference between PDE4 apoenzyme and haloenzyme. Biochemistry 2000; 39: 6449-58
64. Liu S, Laliberte F, Bobechko B, et al. Dissecting the cofactor-dependent and independent bindings of PDE4 inhibitors. Biochemistry 2001; 40: 10179-86
65. Herman SB, Juilfs DM, Fauman EB, et al. Analysis of a mutation in phosphodiesterase type 4 that alters both inhibitor activity and nucleotide selectivity. Mol Pharmacol 2000; 57: 991-9
66. Richter W, Unciuleac L, Hermsdorf T, et al. Identification of inhibitor binding sites of the cAMP-specific phosphodiesterase 4. Cell Signal 2001; 13: 287-97
67. Richter W, Unciuleac L, Hermsdorf T, et al. Identification of substrate specificity determinants in human cAMP-specific phosphodiesterase 4A by single-point mutagenesis. Cell Signal 2001; 13: 159-67
68. Alvarez R, Sette C, Yang D, et al. Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase, PDE-4D3. Mol Pharmacol 1995; 48: 616-22
69. Sette C, Conti M. Phosphorylation and activation of cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase. J Biol Chem 1996; 271: 16526-34
70. O'Connell JC, McCallum JF, McPhee I, et al. The SH3 domain of Src tyrosyl protein kinase interacts with the N-terminal splice region of the PDE4A cAMP-specific phosphodiesterase RPDE-6 (RNPDE4A5). Biochem J 1996; 318: 255-62
71. Hoffman R, Baillie GS, MacKenzie SJ, et al. The MAP kinase ERK2 inhibits the cyclic AMP-specific phosphodiesterase HSPDE3D3 by phosphorylating it at Ser579. EMBO J 1999; 18: 893-903
72. MacKenzie SJ, Baillie GS, McPhee I, et al. ERK2 mitogen-activated protein kinase binding, phosphorylation, and regulation of the PDE4D cAMP-specific phosphodiesterases. J Biol Chem 2000; 275: 16609-17
73. Schneider HH, Schmiechen R, Brezinski M, et al. Stereospecific binding of the antidepressant rolipram to brain protein structures. Eur J Pharmacol 1986; 127: 105-15
74. Nemoz G, Moueqqit M, Prigent AF, et al. Isolation of similar rolipram-inhibitable cyclic-AMP-specific phosphodiesterases from rat-brain and heart. Eur J Biochem 1989; 184: 511-20
75. Perez-Torres S, Miro X, Palacios JM, et al. Phosphodiesterase type 4 isozymes expression in human brain examined by in situ hybridization histochemistry and [3H]rolipram binding autoradiography: comparison with monkey and rat brain. J Chem Neuroanat 2000; 20: 349-74
76. Barnette MS, Grous M, Cieslinski LB, et al. Inhibitors of phosphodiesterase IV (PDE IV) increase acid secretion in rabbit isolated gastric glands: correlation between function and interaction with a high-affinity rolipram binding site. J Pharmacol Exp Ther 1995; 273: 1396-402
77. Duplantier AJ, Biggers MS, Chambers RJ, et al. Biarylcarboxylic acids and amides: inhibition of phosphodiesterase type IV versus [3H]rolipram binding activity and their relationship to emesis in the ferret. J Med Chem 1996; 39: 120-5
78. Barnette MS, Bartus JO, Burman M, et al. Association of the anti-inflammatory activity of phosphodiesterase 4 (PDE4) inhibitors with either inhibition of PDE4 catalytic activity or competition for [3H]rolipram binding. Biochem Pharmacol 1996; 51: 949-56
79. Souness JE, Scott LC. Stereospecificity of rolipram actions on eosinophil cyclic AMP-specific phosphodiesterase. Biochem J 1993; 291: 389-95
80. Souness JE, Houghton C, Sardar N, et al. Evidence that cyclic AMP phosphodiesterase inhibitors suppress interleukin-2 release from murine splenocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer. Br J Pharmacol 1997; 121: 743-50
81. Torphy TJ, Stadel JM, Burman M, et al. Coexpression of human cAMP-specific phosphodiesterase activity and high affinity rolipram binding in yeast. J Biol Chem 1992; 267: 1798-804
82. McLaughlin MM, Cieslinski LB, Burman M, et al. A low K(M), rolipram-sensitive, cAMP-specific phosphodiesterase from human brain: cloning and expression of cDNA, biochemical characterization of recombinant protein, and tissue distribution of messenger-RNA. J Biol Chem 1993; 268: 6470-6
83. Li SH, Chan SC, Toshitani A, et al. Synergistic effects of interleukin 4 and interferon-gamma on monocyte phosphodiesterase activity. J Invest Dermatol 1992; 99: 65-70
84. Li SH, Chan SC, Kramer SM, et al. Modulation of leukocyte cyclic AMP phosphodiesterase activity by recombinant interferon-gamma: evidence for a differential effect on atopic monocytes. J Interferon Res 1993; 13: 197-202
85. MacKenzie SJ, Baillie GS, McPhee I, et al. ERK2 mitogen-activated protein kinase binding, phosphorylation, and regulation of the PDE4D cAMP-specific phosphodiesterases: the involvement of COOH-terminal docking sites and NH2-terminal UCR regions. J Biol Chem 2000; 275: 16609-17
86. Ma D, Wu P, Egan RW, et al. Phosphodiesterase 4B gene transcription is activated by lipopolysaccharide and inhibited by interleukin-10 in human monocytes. Mol Pharmacol 1999; 55: 50-7
87. Dym O, Xenarios I, Ke H, et al. Molecular docking of competitive phosphodiesterase inhibitors. Mol Pharmacol 2002; 61: 20-5
88. 3H]R-(-)-rolipram binding by selective inhibitors. Biochem J 1996; 318: 425-36
89. Carpenter DO, Briggs DB, Knox AP, et al. Excitation of area postrema neurones by transmitters, peptides and cyclic nucleotides. J Neurophysiol 1988; 59: 358-69
90. Robichaud A, Tattersall FD, Choudhury I, et al. Emesis induced by inhibitors of type IV cyclic nucleotide phosphodiesterase (PDE IV) in the ferret. Neuropharmacology 1999; 38: 289-97
91. Andrews PL, Kovacs M, Watson JW. The anti-emetic action of the neurokinin(l) receptor antagonist CP-99,994 does not require the presence of the area postrema in the dog. Neurosci Lett 2001; 314: 102-4
92. Manning CD, Burman M, Christensen SB, et al. Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B. Br J Pharmacol 1999; 128: 1393-8
93. Hersperger R, Bray-French K, Mazzoni L, et al. Palladium-catalyzed cross-coupling reactions for the synthesis of 6, 8-disubstituted 1,7-naphthyridines: a novel class of potent and selective phosphodiesterase type 4D inhibitors. J Med Chem 2000; 43: 675-82
94. Aoki M, Kobayashi M, Ishikawa J, et al. A novel phosphodiesterase type 4 inhibitor, YM976 (4-(3-chlorophenyl)-1,7-diethylpyrido[2,3-d]pyrimidin-2(1H)- one), with little emetogenic activity. J Pharmacol Exp Ther 2000; 295: 255-60
95. Hughes B, Howat D, Lisle H, et al. The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4. Br J Pharmacol 1996; 118: 1183-91
96. Christensen SB, Guider A, Forster CJ, et al. 1,4-Cyclohexane- carboxylates: potent and selective inhibitors of phosphodiesterase 4 for the treatment of asthma. J Med Chem 1998; 41: 821-35
97. Harbinson PL, MacLeod D, Hawksworth R, et al. The effect of a novel orally active selective PDE4 isoenzyme inhibitor (CDP840) on allergen-induced responses in asthmatic subjects. Eur Respir J 1997; 10: 1008-14
98. Barnette MS, Christensen SB, Essayan DM, et al. SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions. J Pharmacol Exp Ther 1998; 284: 420-6
99. Usdin S. Choking on Ariflo. Biocentury. Bernstein Rep Biobusiness 2003; 11: A1-4
100. Gleich GJ. Mechanisms of eosinophil-associated inflammation. J Allergy Clin Immunol 2000; 105: 651-63
101. Romagnani S. The role of lymphocytes in allergic disease. J Allergy Clin Immunol 2000; 105: 399-408
102. Saetta M. Airway inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: S17-20
103. Fujimura M, Kamio Y, Saito M, et al. Bronchodilator and bronchoprotective effects of cilostazol in humans in vivo. Am J Respir Crit Care Med 1995; 151: 222-5
104. Bardin PG, Dorward MA, Lampe FC, et al. Effect of selective phosphodiesterase 3 inhibition on the early and late asthmatic responses to inhaled allergen. Br J Clin Pharmacol 1998; 45: 387-91
105. Myou S, Fujimura M, Kamio Y, et al. Bronchodilator effect of inhaled olprinone, a phosphodiesterase 3 inhibitor, in asthmatic patients. Am J Respir Crit Care Med 1999; 160: 817-20
106. Foster RW, Rakshi K, Carpenter JR, et al. Trials of the bronchodilator activity of the isoenzyme-selective phosphodiesterase inhibitor AH 21-132 in healthy volunteers during a methacholine challenge test. Br J Clin Pharmacol 1992; 34: 527-34
107. Kawasaki A, Hoshino K, Osaki R, et al. Effect of ibudilast: a novel antiasthmatic agent, on airway hypersensitivity in bronchial asthma. J Asthma 1992; 29: 245-52
108. Jonker GJ, Tijhuis GJ, de Monchey JGR. RP 73401 (a phosphodiesterase IV inhibitor) single does not prevent allergen induced bronchoconstriction during the early phase reaction in asthmatics [abstract]. Eur Respir J 1996; 9: 82s
109. Nieman RB, Fisher BD, Amit O, et al. SB 207499 (Ariflow™), a second-generation, selective oral phosphodiesterase type 4 (PDE4) inhibitor, attenuates exercise induced bronchoconstriction in patients with asthma [abstract]. Am J Respir Crit Care Med 1998; 157: A413
110. Nell H, Louw C, Leichtl S, et al. Acute anti-inflammatory effect of the novel phosphodiesterase 4 inhibitor roflumilast on allergen challenge in asthmatics after a single dose [abstract]. Am J Respir Crit Care Med 2000; 161: A200
111. Leichtl S, Schmid-Wirlitsch C, Bredenbroker D, et al. Dose-related efficacy of once-daily roflumilast, a new orally active, selective phosphodiesterase 4 inhibitor, in asthma [abstract]. Am J Respir Crit Care Med 2002; 165: A185
112. Leichtl S, Syed J, Bredenbroker D, et al. Efficacy of once-daily roflumilast, a new orally active, selective phosphodiesterase4 inhibitor, in chronic obstructive pulmonary disease [abstract]. Am J Respir Crit Care Med 2002; 165: A229
113. Jin SL, Richard FJ, Kuo WP, et al. Impaired growth and fertility of cAMP-specific phosphodiesterase PDE4D-deficient mice. Proc Natl Acad Sci U S A 1999; 96: 11998-2003
114. Hansen G, Jin S, Umetsu DT, et al. Absence of muscarinic cholinergic airway responses in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D. Proc Natl Acad Sci U S A 2000; 97: 6751-6
115. Kung TT, Crawley Y, Luo B, et al. Inhibition of pulmonary eosinophilia and airway hyperresponsiveness in allergic mice by rolipram: involvement of endogenously released corticosterone and catecholamines. Br J Pharmacol 2000; 130: 457-63
116. Ikemura T, Schwarze J, Makela M, et al. Type 4 phosphodiesterase inhibitors attenuate respiratory syncytial virus-induced airway hyper-responsiveness and lung eosinophilia. J Pharmacol Exp Ther 2000; 294: 701-6
117. Kanehiro A, Ikemura T, Makela MJ, et al. Inhibition of phosphodiesterase 4 attenuates airway hyperresponsiveness and airway inflammation in a model of secondary allergen challenge. Am J Respir Crit Care Med 2001; 163: 173-84
118. Kemeny DM, Vyas B, Vukmanovi-Stejic M, et al. CD8+ T cell subsets and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: S33-7
119. Bousquet J, Jeffery PK, Busse WW, et al. Asthma: from bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med 2000; 161: 1720-45
120. Jeffery PK. Structural and inflammatory changes in COPD: a comparison with asthma. Thorax 1998; 53: 129-36
121. Persson CGA, Pauwels R. Pharmacology of anti-asthma xanthines. In: Page CP, Barnes PJ, editors. Pharmacology of asthma. Berlin: Springer-Verlag, 1991: 207-25
122. Nicholson CD, Shahid M. Inhibitors of cyclic nucleotide phosphodiesterase isoenzymes: their potential utility in the therapy of asthma. Pulm Pharmacol 1994; 7: 1-17
123. Ward AJ, McKenniff M, Evans JM, et al. Theophylline: an immunomodulatory role in asthma? Am Rev Respir Dis 1993 ; 147: 518-23
124. Sullivan P, Bekir S, Jaffar Z, et al. Anti-inflammatory effects of low-dose oral theophylline in atopic asthma [published erratum appears in Lancet 1994 Jun 11; 343 (8911): 1512]. Lancet 1994; 343: 1006-8
125. Kidney J, Dominguez M, Taylor PM, et al. Immunomodulation by theophylline in asthma: demonstration by withdrawal of therapy. Am J Respir Crit Care Med 1995; 151: 1907-14
126. Kraft M, Torvik JA, Trudeau JB, et al. Theophylline: potential antiinflammatory effects in nocturnal asthma. J Allergy Clin Immunol 1996; 97: 1242-6
127. Ashutosh K, Sedat M, Fragale-Jackson J. Effects of theophylline on respiratory drive in patients with chronic obstructive pulmonary disease. J Clin Pharmacol 1997; 37: 1100-7
128. Jaffar ZH, Sullivan P, Page CP, et al. Low-dose theophylline modulates T-lymphocyte activation in allergen-challenged asthmatics. Eur Respir J 1996; 9: 456-62
129. Hidi R, Timmermans S, Liu E, et al. Phosphodiesterase and cyclic adenosine monophosphate-dependent inhibition of T-lymphocyte chemotaxis. Eur Respir J 2000; 15: 342-9
130. Finnerty JP, Lee C, Wilson S, et al. Effects of theophylline on inflammatory cells and cytokines in asthmatic subjects: a placebo-controlled parallel group study. Eur Respir J 1996; 9: 1672-7
131. Brenner M, Berkowitz R, Marshall N, et al. Need for theophylline in severe steroid-requiring asthmatics. Clin Allergy 1988; 18: 143-50
132. Yasui K, Hu B, Nakazawa T, et al. Theophylline accelerates human granulocyte apoptosis not via phosphodiesterase inhibition. J Clin Invest 1997; 100: 1677-84
133. Banner KH, Hoult JR, Taylor MN, et al. Possible contribution of prostaglandin E2 to the antiproliferative effect of phosphodiesterase 4 inhibitors in human mononuclear cells. Biochem Pharmacol 1999; 58: 1487-95
134. Peterson TC, Slysz G, Isbrucker R. The inhibitory effect of ursodeoxycholic acid and pentoxifylline on platelet derived growth factor-stimulated proliferation is distinct from an effect by cyclic AMP. Immunopharmacology 1998; 39: 181-91
135. Persson CG Pauwels R. Pharmacology of anti-asthma xanthines. In: Page CP, Barnes PJ, editors. Pharmacology of asthma. London: Academic Press, 1989: 207-25
136. Pauwels R, van Renterghem D, van der Straeten M, et al. The effect of theophylline and enprofylline on allergen-induced bronchoconstriction. J Allergy Clin Immunol 1985; 76: 583-90
137. Feoktistov I, Biaggioni I. Adenosine A2b receptors evoke interleukin-8 secretion in human mast cells: an enprofylline-sensitive mechanism with implications for asthma. J Clin Invest 1995; 96: 1979-86
138. Feoktistov I, Polosa R, Holgate ST, et al. Adenosine A2B receptors: a novel therapeutic target in asthma? Trends Pharmacol Sci 1998; 19: 148-53
139. Cushley MJ, Tattersfield AE, Holgate ST. Inhaled adenosine and guanosine on airway resistance in normal and asthmatic subjects. Br J Clin Pharmacol 1983; 15: 161-5
140. Cushley MJ, Tattersfield AE, Holgate ST. Adenosine-induced bronchoconstriction in asthma. Antagonism by inhaled theophylline. Am Rev Respir Dis 1984; 129: 380-4
141. Mann JS, Holgate ST. Specific antagonism of adenosine-induced bronchoconstriction in asthma by oral theophylline. Br J Clin Pharmacol 1985; 19: 685-92
142. el Hashim A, D' AgostinoB, Matera MG, et al. Characterization of adenosine receptors involved in adenosine-induced bronchoconstriction in allergic rabbits. Br J Pharmacol 1996; 119: 1262-8
143. Nyce JW, Metzger WJ. DNA antisense therapy for asthma in an animal model. Nature 1997; 385: 721-5
144. Yasui K, Agematsu K, Shinozaki K, et al. Theophylline induces neutrophil apoptosis through adenosine A2A receptor antagonism. J Leukoc Biol 2000; 67: 529-35
145. Ezeamuzie CI. Involvement of A(3) receptors in the potentiation by adenosine of the inhibitory effect of theophylline on human eosinophil degranulation: possible novel mechanism of the anti-inflammatory action of theophylline. Biochem Pharmacol 2001; 61: 1551-9
146. Landells LJ, Jensen MW, Orr LM, et al. The role of adenosine receptors in the action of theophylline on human peripheral blood mononuclear cells from healthy and asthmatic subjects. Br J Pharmacol 2000; 129: 1140-4
147. Foukas LC, Daniele N, Ktori C, et al. Direct effects of caffeine and theophylline on the p110d and other phosphoinositide 3-Kinases: differential effects on lipid Kinase and protein Kinase activity. J Biol Chem 2002; 277: 37124-30
148. Ito K, Lim S, Caramori G, et al. A molecular mechanism of action of theophylline: induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci USA 2002; 99: 8921-6
149. Gamble E, Grootendorst DC, Brightling CE, et al. Antiinflammatory effects of the phosphodiesterase inhibitor cilomilast (Ariflo) in COPD. Am J Respir Crit Care Med. Epub 2003 Jun 19
150. Underwood DC, Bochnowicz S, Osborn RR, et al. Antiasthmatic activity of the second-generation phosphodiesterase 4 (PDE4) inhibitor SB 207499 (Ariflo) in the guinea pig. J Pharmacol Exp Ther 1998; 287: 988-95
151. Bundschuh DS, Eltze M, Barsig J, et al. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp Ther 2001; 297: 280-90
152. Parker CW, Kennedy S, Eisen AZ. Leukocyte and lymphocyte cyclic AMP responses in atopic eczema. J Invest Dermatol 1977; 68: 302-6
153. Archer CB, Morley J, MacDonald DM. Impaired lymphocyte cyclic adenosine monophosphate responses in atopic eczema. Br J Dermatol 1983; 109: 559-64
154. Safko MJ, Chan SC, Cooper KD, et al. Heterologous desensitization of leukocytes: a possible mechanism of beta adrenergic blockade in atopic dermatitis. J Allergy Clin Immunol 1981; 68: 218-25
155. Grewe SR, Chan SC, Hanifin JM. Elevated leukocyte cyclic AMP-phosphodiesterase in atopic disease: a possible mechanism for cyclic AMP-agonist hyporesponsiveness. J Allergy Clin Immunol 1982; 70: 452-7
156. Chan SC, Reifsnyder D, Beavo JA, et al. Immunochemical characterization of the distinct monocyte cyclic AMP-phosphodiesterase from patients with atopic dermatitis. J Allergy Clin Immunol 1993; 91: 1179-88
157. Hanifin JM, Chan SC. Monocyte phosphodiesterase abnormalities and dysregulation of lymphocyte function in atopic dermatitis. J Invest Dermatol 1995; 105: 84S-8S
158. Giustina TA, Chan SC, Thiel ML, et al. Increased leukocyte sensitivity to phosphodiesterase inhibitors in atopic dermatitis: tachyphylaxis after theophylline therapy. J Allergy Clin Immunol 1984; 74: 252-7
159. Hanifin JM, Chan SC, Cheng JB, et al. Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J Invest Dermatol 1996; 107: 51-6
160. Banner KH, Roberts NM, Page CP. Differential effect of phosphodiesterase 4 inhibitors on the proliferation of human peripheral blood mononuclear cells from normals and subjects with atopic dermatitis. Br J Pharmacol 1995; 116: 3169-74
161. Stawiski MA, Rusin LJ, Burns TL, et al. Ro 20-1724: an agent that significantly improves psoriatic lesions in double-blind clinical trials. J Invest Dermatol 1979; 73: 261-3
162. Koeter GH, Meurs H, Kauffman HF, et al. The role of the adrenergic system in allergy and bronchial hyperreactivity. Eur J Respir Dis Suppl 1982; 121: 72-8
163. Meurs H, Koeter GH, de Vries K, et al. The beta-adrenergic system and allergic bronchial asthma: changes in lymphocyte beta-adrenergic receptor number and adenylate cyclase activity after an allergen-induced asthmatic attack. J Allergy Clin Immunol 1982; 70: 272-80
164. Bachelet M, Vincent D, Havet N, et al. Reduced responsiveness of adenylate cyclase in alveolar macrophages from patients with asthma. J Allergy Clin Immunol 1991; 88: 322-8
165. Beusenberg FD, Van Amsterdam JGC, Hoogsteden HC, et al. Stimulation of cyclic AMP production in human alveolar macrophages induced by inflammatory mediators and beta-sympathicomimetic. Eur J Pharmacol 1992; 228: 57-62
166. Tenor H, Staniciu L, Schudt C, et al. Cyclic nucleotide phosphodiesterases from purified human CD4+ and CD8+ T lymphocytes. Clin Exp Allergy 1995; 25: 616-24
167. Aloui R, Gormand F, Prigent AF, et al. Increased respiratory burst and phosphodiesterase activity in alveolar eosinophils in chronic eosinophilic pneumonia. Eur Respir J 1996; 9: 377-9
168. Landells LJ, Spina D, Souness J, et al. A biochemical and functional assessment of monocyte phosphodiesterase activity in healthy and asthmatic subjects. Pulm Pharmacol Ther 2000; 13 (5): 231-9
169. Sawai T, Ikai K, Uehara M. Cyclic adenosine monophosphate phosphodiesterase activity in peripheral blood mononuclear leukocytes from patients with atopic dermatitis: correlation with respiratory atopy. Br J Dermatol 1998; 138: 846-8
170. Busse WW, Anderson CL. The granulocyte response to the phosphodiesterase inhibitor RO 20-1724 in asthma. J Allergy Clin Immunol 1981; 67: 70-4
171. Crocker IC, Ohia SE, Church MK, et al. Phosphodiesterase type 4 inhibitors, but not glucocorticoids, are more potent in suppression of cytokine secretion by mononuclear cells from atopic than nonatopic donors. J Allergy Clin Immunol 1998; 102: 797-804
172. Landells LJ, Szilagy CM, Jones NA, et al. Identification and quantification of phosphodiesterase 4 subtypes in CD4 and CD8 lymphocytes from healthy and asthmatic subjects. Br J Pharmacol 2001; 133: 722-9
173. Brunnee T, Engelstatter R, Steinijans VW, et al. Bronchodilatory effect of inhaled zardaverine, a phosphodiesterase III and IV inhibitor, in patients with asthma. Eur Respir J 1992; 5: 982-5
174. Holbrook M, Gozzard N, James T, et al. Inhibition of bronchospasm and ozone-induced airway hyperresponsiveness in the guinea-pig by CDP840, a novel phosphodiesterase type 4 inhibitor. Br J Pharmacol 1996; 118: 1192-200
175. Juilfs DM, Fulle HJ, Zhao AZ, et al. A subset of olfactory neurons that selectively express cGMP-stimulated phosphodiesterase (PDE2) and guanylyl cyclase-D define a unique olfactory signal transduction pathway. Proc Natl Acad Sci U S A 1997; 94: 3388-95
176. Hunter DD, Myers AC, Undem BJ. Nerve growth factor-induced phenotypic switch in guinea pig airway sensory neurons. Am J Respir Crit Care Med 2000; 161: 1985-90